CCI
AERI

Columbus Circle Investors’s Aerie Pharmaceuticals AERI Stock Holding History

Columbus Circle Investors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25,800
Closed -$974K – 312
2016
Q3 		$974K Buy
+25,800
New +$569K 0.01% 252

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Columbus Circle Investors's AERI Position: Q1 2019 in Review

Columbus Circle Investors sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 598,830 shares — an estimated $21.6M sold.

Columbus Circle Investors first reported a position in AERI in Q1 2014 and held it in 20 quarters. The position peaked at $52.3M in Q2 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

  • Columbus Circle Investors reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Columbus Circle Investors sold 598,830 Aerie Pharmaceuticals shares in Q1 2019, an estimated $21.6M.
  • Columbus Circle Investors first reported a position in Aerie Pharmaceuticals in Q1 2014 and held it in 20 quarters.
  • Columbus Circle Investors's Aerie Pharmaceuticals position peaked at $52.3M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on Columbus Circle Investors's 13F filing for Q1 2019, filed 22 Apr 2019.